Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy

利用 PD-1 的力学生物学进行癌症免疫治疗

• 批准号: 10524207
• 负责人: Rafi Ahmed
• 金额: $ 7.9万
• 依托单位: GEORGIA INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10524207
• 关键词: Adoptive Cell Transfers; Amino Acids; Antigens; Binding; CD28 gene; CD4 Antigens; CD8 receptor; CD8-Positive T-Lymphocytes; CD8B1 gene; Cancer Vaccines; Cell Differentiation process; Cell physiology; Cells; Chronic; Communicable Diseases; Complex; Coupled; Crystallization; Cytokine Receptors; Cytotoxic T-Lymphocytes; DNA; Data; Devices; Discrimination; Disease; Dissociation; Engineering; Foundations; Generations; Goals; Human; Image; Immunologist; Immunotherapy; In Situ; In Vitro; Investigation; Kinetics; Ligands; Major Histocompatibility Complex; Malignant Neoplasms; Mechanics; Mediating; Memory; Methods; Microfluidics; Modeling; Molecular; Molecular Conformation; Mus; Mutate; Oncology; Peptide Receptor; Peptides; Receptor Signaling; Regulation; Reporting; Signal Transduction; Solid; Structure; T cell differentiation; T cell response; T cell therapy; T memory cell; T-Cell Activation; T-Cell Receptor; T-Lymphocyte; T-Lymphocyte Subsets; Testing; Therapeutic; Thinking; Tumor Immunity; Vaccination; Vaccine Therapy; Virus Diseases; acute infection; adaptive immunity; base; cancer immunotherapy; cell killing; cellular imaging; chemokine receptor; exhaustion; gp100 Antigen; improved; in silico; in vivo; insight; melanoma; molecular dynamics; mouse model; multidisciplinary; novel strategies; physical science; programmed cell death ligand 1; programmed cell death protein 1; receptor; response; single molecule; stem; stem-like cell; synergism; tool; tumor

PROJECT SUMMARY Programmed cell death 1 (PD-1) is one of the key co-inhibitory molecules upregulated upon T cell activation and is a hallmark of T-cell exhaustion. Despite the fact that PD-1 blockade has become a revolutionary strategy in treating cancer and infectious diseases, the mechanobiology of PD-1 has not been studied. This is the gap that tne present Physical Science – Oncology Project (PS-OP) aims to fill. The significance of the PS-OP’s unique mechanobiology angle lies in the therapeutic potential of targeting the mechanoregulation of PD-1 to treat a wide variety of diseases, including melanoma, which is the focus of this PS-OP. The approaches of the PS-OP’s multidisciplinary team combine four physical science (PS) tools with two mouse models of melanoma. They represent the unique strength of the Zhu lab and the Ahmed lab, and enable investigation of PD-1 mechanobiology in silico, in vitro and in vivo. The first PS tool is DNA-based mechanical tension probes (MTP) and tension gauge tethers (TGT) that report and limit, respectively, cell-generated forces on PD-1. The second PS tool is three biomembrane force probe (BFP)-based single-molecule methods that quantify force regulation of in situ PD-1–PD-ligand interactions with concurrent imaging of intracellular signals in single cells. The third PS tool is molecular dynamics (MD) simulations that reveal structural changes of PD-1 in complex with its ligands under force and the bonding dynamics at atomic level. The fourth PS-tool is microfluidic-based devices for cell trapping, stimulation, and analysis. Preliminary studies of the project demonstrate that: 1) cells actively pull on PD-1; 2) force on PD-1 elicits catch bonds to regulate ligand bonding; 3) force induces rearrangement of the PD- 1–PD-L2 binding interface to form new atomic-level interactions; 4) mutating specific amino acids on PD-1 alters its force, catch bond and function; and 5) PD-1’s inhibitory signal suppresses antigen recognition by disrupting the synergy between TCR and CD8 in pMHC binding. These data support the hypothesis that force critically regulates ligand bonding and signaling of PD-1; as such, targeting the PD-1 mechanoregulation may represent a novel approach to immunotherapy. This hypothesis will be tested by three specific aims: 1) Determine the forces on PD-1 and their impact on PD-1 ligand bonding, signaling and function; 2) Modulate T cell function by targeting PD-1 mechanoregulation; and 3) Investigate the therapeutic potential of manipulating PD-1 catch bonds in tumor mouse models. These studies will elucidate the mechanisim of PD-1 signaling, improve one’s understanding of CD8+ T-cell responses to melanoma, and suggest new immunotheraputic strategies to treating cancer.

项目总结 程序性细胞死亡1(PD-1)是T细胞活化和上调的关键共抑制分子之一。 是T细胞衰竭的标志。尽管PD-1封锁已经成为一项革命性的战略 在治疗癌症和传染病方面，PD-1的机制生物学还没有得到研究。这就是差距， 目前的物理科学-肿瘤学计划(PS-OP)旨在填补。PS-OP独一无二的意义 机制生物学角度在于靶向PD-1机制调节治疗广泛性骨髓瘤的治疗潜力 各种疾病，包括黑色素瘤，这是这次PS-OP的重点。PS-OP的方法 多学科团队结合了四种物理科学(PS)工具和两种黑色素瘤小鼠模型。他们 代表朱实验室和艾哈迈德实验室的独特优势，并使PD-1的调查成为可能 硅胶、体外和体内的机械生物学。第一个PS工具是基于DNA的机械张力探针(MTP) 和张力计系绳(TGT)，分别报告和限制PD-1上的细胞生成力。第二 PS工具是基于生物膜力探头(BFP)的三种定量化力量调节的单分子方法 原位PD-1-PD配基相互作用与单细胞内细胞内信号的同时成像。第三 PS工具是分子动力学(MD)模拟，揭示了PD-1与其配体形成的络合物的结构变化 力和原子水平上的成键动力学。第四个PS工具是基于微流控技术的电池设备 诱捕、刺激和分析。该项目的初步研究表明：1)细胞主动拉动 Pd-1；2)对Pd-1的作用力引起捕获键，以调节配基结合；3)作用力诱导Pd-1重排。 1-PD-L2结合界面形成新的原子水平相互作用；4)突变PD-1上的特定氨基酸改变 5)PD-1‘S抑制信号通过干扰抗原识别而抑制抗原识别 TCR和CD8在pMHC结合中的协同作用。这些数据支持这样一种假设，即 调节PD-1的配体结合和信号传递；因此，靶向PD-1的机械调节可能代表 一种新的免疫治疗方法。这一假设将通过三个具体目标进行检验：1)确定 对PD-1的作用力及其对PD-1配体结合、信号和功能的影响；2)通过以下方式调节T细胞功能 靶向PD-1机械调节；以及3)研究操纵PD-1捕获键的治疗潜力 在肿瘤小鼠模型中。这些研究将阐明PD-1信号转导的机制，改善人们的 了解CD8+T细胞对黑色素瘤的反应，并建议新的免疫治疗策略 癌症。